Susann Cattepoel

Title: Susann Cattepoel: Innovator in Humanized Antibodies

Introduction

Susann Cattepoel is a prominent inventor based in Zurich, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of two patents to her name, her work focuses on innovative solutions for medical diagnostics and treatment.

Latest Patents

Cattepoel's latest patents include groundbreaking inventions related to humanized antibodies against the beta-amyloid peptide. The first patent discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is either humanized or fully human. This antibody is capable of preventing the oligomerization of Abeta, which is crucial in the context of neurodegenerative diseases. Additionally, the patent outlines a method of diagnosis that involves labeling an antibody, administering an effective dose intranasally or systemically to a subject, and detecting the concentration and/or presence of the labeled antibody in various body parts of the subject.

Career Highlights

Throughout her career, Susann Cattepoel has worked with notable organizations such as Delenex Therapeutics AG and the University of Zurich. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to significant advancements in biotechnology.

Collaborations

Some of her notable coworkers include Stefan Ewert and Adrian Auf Der Maur. Their collaborative efforts have further enhanced the impact of her research and innovations.

Conclusion

Susann Cattepoel's work in the field of humanized antibodies represents a significant advancement in medical science. Her innovative patents and collaborations highlight her dedication to improving diagnostic and therapeutic methods.